Insider Selling: Progyny (NASDAQ:PGNY) EVP Sells 599 Shares of Stock

Progyny, Inc. (NASDAQ:PGNY) EVP Allison Swartz sold 599 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $17.54, for a total value of $10,506.46. Following the transaction, the executive vice president directly owned 88,941 shares of the company’s stock, valued at $1,560,025.14. The trade was a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Allison Swartz also recently made the following trade(s):

• On Tuesday, March 3rd, Allison Swartz sold 4,657 shares of Progyny stock. The shares were sold at an average price of $17.40, for a total value of $81,031.80.
• On Monday, March 2nd, Allison Swartz sold 2,199 shares of Progyny stock. The stock was sold at an average price of $17.27, for a total value of $37,976.73.

Progyny Price Performance

Shares of PGNY stock traded up $0.69 during trading hours on Friday, reaching $18.31. 1,805,320 shares of the stock were exchanged, compared to its average volume of 1,628,731. The business’s fifty day moving average is $23.24 and its two-hundred day moving average is $22.96. The firm has a market capitalization of $1.50 billion, a P/E ratio of 28.17, a P/E/G ratio of 1.21 and a beta of 1.01. Progyny, Inc. has a 12-month low of $16.75 and a 12-month high of $28.75.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. The company had revenue of $318.40 million for the quarter, compared to the consensus estimate of $314.26 million. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.42 EPS. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. As a group, equities research analysts predict that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Progyny

Several hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in Progyny by 2.4% during the 3rd quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock valued at $217,484,000 after acquiring an additional 235,513 shares during the last quarter. State Street Corp increased its holdings in shares of Progyny by 1.5% in the fourth quarter. State Street Corp now owns 2,953,186 shares of the company’s stock valued at $75,838,000 after purchasing an additional 44,642 shares during the period. Wellington Management Group LLP raised its stake in shares of Progyny by 260.9% during the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock worth $57,607,000 after purchasing an additional 1,621,688 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Progyny by 37.6% during the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after purchasing an additional 545,431 shares during the period. Finally, Geode Capital Management LLC grew its position in Progyny by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 1,972,219 shares of the company’s stock valued at $50,655,000 after buying an additional 20,533 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on PGNY. BTIG Research cut their price objective on shares of Progyny from $35.00 to $30.00 and set a “buy” rating on the stock in a report on Thursday. Zacks Research downgraded shares of Progyny from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Citizens Jmp raised shares of Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 price target for the company in a research report on Tuesday, January 20th. KeyCorp decreased their price objective on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday. Finally, Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Nine equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $29.09.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.